Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

Seventeen subjects in the Brilacidin ph2a proof of concept trial appears to have been sufficient for Alfasigma to move it forward. And, I agree that FDA will want a larger trial for a ph2b or 3. It will be interesting to see what is required in the EU.

http://www.ipharminc.com/press-release/2019/7/22/innovation-pharmaceuticals-announces-license-agreement-with-alfasigma-spa-for-the-development-and-commercialization-of-brilacidin-in-ulcerative-proctitis-ulcerative-proctosigmoiditis





In Reply to 'JTORENCE'
Wow 17 patients. Earth shattering. FDA will get a good laugh when he presents trial results for anything under a few hundred patients. imo